Skip to main content
Top
Published in: Japanese Journal of Radiology 9/2015

01-09-2015 | Original Article

Multicentre study of 18F-FDG-PET/CT prostate incidental uptake

Authors: Francesco Bertagna, Arnoldo Piccardo, Bassam Dib, Mattia Bertoli, Federica Fracassi, Giovanni Bosio, Raffaele Giubbini, Giorgio Biasiotto, Luca Giovanella, Giorgio Treglia

Published in: Japanese Journal of Radiology | Issue 9/2015

Login to get access

Abstract

Aim

The purpose of our study was to establish the prevalence and pathological nature of fluorine-18-fluorodeoxyglucose (18F-FDG) prostate incidental uptake (PIU) among patients studied for non-prostate-malignant purposes in three nuclear medicine centres.

Methods

We retrospectively evaluated 20,422 scans performed on male patients; all patients underwent 18F-FDG-PET/CT for purposes not related to prostate disease.

Results

Among 20,422 patients PIU was identified for 280 (1.4 %) with an average age of 70 ± 10.7 years. Sixty-three of the 280 patients with PIU (22.5 %) underwent PSA dosage and biopsy to determine the nature of the incidental uptake. Thirty-five of the 63 (55.5 %) PIU were malignant whereas 28/63 (44.5 %) were benign. The average value of PSA for patients with benign PIU was 3.7 ± 2.8 ng/ml whereas it was 7.8 ± 8.2 ng/ml in patients with malignant PIU; this difference was statistically significant. For malignant lesions, the average lesion-to-liver SUVmax ratio was 2.9 ± 2.5 and the average lesion-to-blood-pool SUVmax ratio was 3.7 ± 2.5. For benign lesions, the average lesion-to-liver SUVmax ratio was 2.5 ± 1.7 and the average lesion-to-blood-pool SUVmax ratio was 3.5 ± 2.4; there was no statistically significant difference between lesion-to-liver and lesion-to-blood-pool SUVmax ratios for benign and malignant lesions.

Conclusion

Because PIU values are indicative of malignancy for a substantial percentage of patients, further investigation is required.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M, et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer (IARC). http://globocan.iarc.fr. Accessed 13 January 2015. Ferlay J, Soerjomataram I, Ervik M, et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer (IARC). http://​globocan.​iarc.​fr. Accessed 13 January 2015.
2.
go back to reference Bertagna F, Sadeghi R, Giovanella L, Treglia G. Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland. Systematic review and meta-analysis on prevalence and risk of malignancy. Nuklearmedizin. 2014;53:249–58.CrossRefPubMed Bertagna F, Sadeghi R, Giovanella L, Treglia G. Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland. Systematic review and meta-analysis on prevalence and risk of malignancy. Nuklearmedizin. 2014;53:249–58.CrossRefPubMed
3.
go back to reference Bertagna F, Treglia G, Piccardo A, Giovannini E, Bosio G, Biasiotto G, et al. FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value. Endocrine. 2013;43:678–85.CrossRefPubMed Bertagna F, Treglia G, Piccardo A, Giovannini E, Bosio G, Biasiotto G, et al. FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value. Endocrine. 2013;43:678–85.CrossRefPubMed
4.
go back to reference Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012;97:3866–75.CrossRefPubMed Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012;97:3866–75.CrossRefPubMed
5.
go back to reference Bertagna F, Treglia G, Orlando E, Dognini L, Giovanella L, Sadeghi R, et al. Prevalence and clinical significance of incidental 18F-FDG breast uptake: a systematic review and meta-analysis. Jpn J Radiol. 2014;32:59–68.CrossRefPubMed Bertagna F, Treglia G, Orlando E, Dognini L, Giovanella L, Sadeghi R, et al. Prevalence and clinical significance of incidental 18F-FDG breast uptake: a systematic review and meta-analysis. Jpn J Radiol. 2014;32:59–68.CrossRefPubMed
6.
go back to reference Bertagna F, Evangelista L, Piccardo A, Bertoli M, Bosio G, Giubbini R, Orlando E, Treglia G. Multicentric study on 18F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes. Rev Esp Med Nucl Imagen Mol. 2014. doi:10.1016/j.remn.2014.08.003. Bertagna F, Evangelista L, Piccardo A, Bertoli M, Bosio G, Giubbini R, Orlando E, Treglia G. Multicentric study on 18F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes. Rev Esp Med Nucl Imagen Mol. 2014. doi:10.​1016/​j.​remn.​2014.​08.​003.
7.
go back to reference Gill RS, Perry T, Abele JT, Bédard EL, Schiller D. The clinical significance of incidental intra-abdominal findings on positron emission tomography performed to investigate pulmonary nodules. World J Surg Oncol. 2012;10:25.PubMedCentralCrossRefPubMed Gill RS, Perry T, Abele JT, Bédard EL, Schiller D. The clinical significance of incidental intra-abdominal findings on positron emission tomography performed to investigate pulmonary nodules. World J Surg Oncol. 2012;10:25.PubMedCentralCrossRefPubMed
8.
go back to reference Treglia G, Calcagni ML, Rufini V, Leccisotti L, Meduri GM, Spitilli MG, et al. Clinical significance of incidental focal colorectal (18)F-fluorodeoxyglucose uptake: our experience and a review of the literature. Colorectal Dis. 2012;14:174–80.CrossRefPubMed Treglia G, Calcagni ML, Rufini V, Leccisotti L, Meduri GM, Spitilli MG, et al. Clinical significance of incidental focal colorectal (18)F-fluorodeoxyglucose uptake: our experience and a review of the literature. Colorectal Dis. 2012;14:174–80.CrossRefPubMed
9.
go back to reference Hyun SH, Choi JY, Lee KH, Choe YS, Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med. 2011;52:547–50.CrossRefPubMed Hyun SH, Choi JY, Lee KH, Choe YS, Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med. 2011;52:547–50.CrossRefPubMed
10.
go back to reference Treglia G, Bertagna F, Sadeghi R, Muoio B, Giovanella L. Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis. Eur Arch Otorhinolaryngol. 2014. doi:10.1007/s00405-014-3308-8.PubMed Treglia G, Bertagna F, Sadeghi R, Muoio B, Giovanella L. Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis. Eur Arch Otorhinolaryngol. 2014. doi:10.​1007/​s00405-014-3308-8.PubMed
11.
go back to reference Bhosale P, Balachandran A, Vikram R, et al. what is the clinical significance of FDG unexpected uptake in the prostate in patients undergoing PET/CT for other malignancies? Int J Mol Imaging. 2013;2013:476786.PubMedCentralCrossRefPubMed Bhosale P, Balachandran A, Vikram R, et al. what is the clinical significance of FDG unexpected uptake in the prostate in patients undergoing PET/CT for other malignancies? Int J Mol Imaging. 2013;2013:476786.PubMedCentralCrossRefPubMed
12.
go back to reference Cho SK, Choi JY, Yoo J, et al. Incidental focal 18F-FDG uptake in the prostate: clinical significance and differential diagnostic criteria. Nucl Med Mol Imaging. 2011;45:192–6.PubMedCentralCrossRefPubMed Cho SK, Choi JY, Yoo J, et al. Incidental focal 18F-FDG uptake in the prostate: clinical significance and differential diagnostic criteria. Nucl Med Mol Imaging. 2011;45:192–6.PubMedCentralCrossRefPubMed
13.
go back to reference Han EJ, HO J, Choi WH, et al. Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images. Br J Radiol. 2010;83:915–20.PubMedCentralCrossRefPubMed Han EJ, HO J, Choi WH, et al. Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images. Br J Radiol. 2010;83:915–20.PubMedCentralCrossRefPubMed
14.
go back to reference Hwang I, Chong A, Jung SI, et al. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 2013;27:140–5.CrossRefPubMed Hwang I, Chong A, Jung SI, et al. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 2013;27:140–5.CrossRefPubMed
15.
go back to reference Ozkol V, Alper E, Aydin N, et al. The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography. Nucl Med Commun. 2010;31:128–36.CrossRefPubMed Ozkol V, Alper E, Aydin N, et al. The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography. Nucl Med Commun. 2010;31:128–36.CrossRefPubMed
16.
go back to reference Seino H, Ono S, Miura H, et al. Incidental prostate 18F-FDG uptake without calcification indicates the possibility of prostate cancer. Oncol Rep. 2014;31:1517–22.PubMedCentralPubMed Seino H, Ono S, Miura H, et al. Incidental prostate 18F-FDG uptake without calcification indicates the possibility of prostate cancer. Oncol Rep. 2014;31:1517–22.PubMedCentralPubMed
17.
go back to reference Yang Z, Hu S, Cheng J, et al. Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Clin Imaging. 2014;38:470–4.CrossRefPubMed Yang Z, Hu S, Cheng J, et al. Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Clin Imaging. 2014;38:470–4.CrossRefPubMed
18.
go back to reference Kang PM, Seo WI, Lee SS, et al. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans. Asian Pac J Cancer Prev. 2014;15:8699–703.CrossRefPubMed Kang PM, Seo WI, Lee SS, et al. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans. Asian Pac J Cancer Prev. 2014;15:8699–703.CrossRefPubMed
19.
go back to reference Godoy A, Ulloa V, Rodriguez F, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol. 2006;207:614–27.CrossRefPubMed Godoy A, Ulloa V, Rodriguez F, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol. 2006;207:614–27.CrossRefPubMed
21.
go back to reference Reinicke K, Sotomayor P, Cisterna P, et al. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem. 2012;113:553–62.CrossRefPubMed Reinicke K, Sotomayor P, Cisterna P, et al. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem. 2012;113:553–62.CrossRefPubMed
22.
go back to reference Minamimoto R, Uemura H, Sano F, et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 2011;25:21–7.CrossRefPubMed Minamimoto R, Uemura H, Sano F, et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 2011;25:21–7.CrossRefPubMed
23.
go back to reference Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999;1999(36):31–5.CrossRef Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999;1999(36):31–5.CrossRef
24.
go back to reference Shiiba M, Ishihara K, Kimura G, et al. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 2012;2012(26):138–45.CrossRef Shiiba M, Ishihara K, Kimura G, et al. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 2012;2012(26):138–45.CrossRef
25.
go back to reference Effert P, Beniers AJ, Tamimi Y, et al. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057–63.PubMed Effert P, Beniers AJ, Tamimi Y, et al. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057–63.PubMed
Metadata
Title
Multicentre study of 18F-FDG-PET/CT prostate incidental uptake
Authors
Francesco Bertagna
Arnoldo Piccardo
Bassam Dib
Mattia Bertoli
Federica Fracassi
Giovanni Bosio
Raffaele Giubbini
Giorgio Biasiotto
Luca Giovanella
Giorgio Treglia
Publication date
01-09-2015
Publisher
Springer Japan
Published in
Japanese Journal of Radiology / Issue 9/2015
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-015-0453-y

Other articles of this Issue 9/2015

Japanese Journal of Radiology 9/2015 Go to the issue